ClinicalTrials.gg
CompletedNCT01122264Updated Oct 19, 2012Results posted

A Study in Patients With Erectile Dysfunction

A Phase 4 interventional study of Tadalafil and Sildenafil Citrate in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 45 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-19.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
5th of 56
770 · median 199
Started
2010
with 2 others
Phase 4
26 of 57
3 open now
Registered
27th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 5th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2010, is one of 26 in phase 4, and was the 27th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over 24 weeks), compared with a short-acting drug (Sildenafil Citrate) taken as needed.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Erectile Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of Erectile Dysfunction (ED) of at least 3 months duration.
  • Anticipate having the same adult female sexual partner during the study.
  • Agree not to use any other treatment for ED and to participate in recording responses to questionnaires and other instruments used in this study.

Exclusion criteria

Exclusion Criteria:

  • Previous or current treatment with tadalafil or any other phosphodiesterase type 5 (PDE5) inhibitor.
  • ED caused by other primary sexual disorders, history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection, or history of penile implant or penile deformity.
  • ED caused by untreated or inadequately treated endocrine disease.
  • Current treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens.
  • Severe renal or hepatic impairment, history of malignant hypertension.
  • Presence or history of specific heart conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    Tadalafil on demand

    10 milligrams (mg) or 20 mg on demand

    Drug: Tadalafil

  • Experimental
    Tadalafil once a day

    5 mg or 2.5 mg once a day

    Drug: Tadalafil

  • Active comparator
    Sildenafil Citrate

    50 mg, 100 mg, or 25 mg on demand

    Drug: Sildenafil Citrate

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Discontinuation of Randomized Treatment

    Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.

    Time frame: Baseline up to 334 days

Secondary outcomes

  1. Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain

    Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  2. Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain

    Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  3. Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain

    Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  4. Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)

    Participant-assessed diary. Has 5 questions (Question\[Q\]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit\*treatment.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  5. Global Assessment Questions (GAQ)

    The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?

    Time frame: 24 weeks

  6. Number of Treatment Switches

    The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).

    Time frame: Baseline through 24 weeks

  7. Patterns of Erectile Dysfunction Treatment Change

    Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.

    Time frame: Baseline through 24 weeks

  8. Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment

    The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.

    Time frame: Baseline through 24 weeks

  9. Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments

    The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.

    Time frame: 8 weeks up to 334 days

  10. Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain

    Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  11. Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain

    Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  12. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks

    The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit\*treatment.

    Time frame: 4, 8, 16, and 24 weeks

  13. Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)

    The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score\*treatment (if p\<0.10).

    Time frame: Baseline, 24 weeks

  14. Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

    SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  15. Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

    SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem \[items 9-12\]; Overall Relationship \[items 13-14\]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x\[(actual raw score-lowest possible raw score)/possible raw score range\]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  16. Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

    SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

  17. Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

    SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

    Time frame: Baseline, 4, 8, 16, and 24 weeks

07

Results

Posted Oct 19, 2012

Participant flow

Participant flow — Overall Study
MilestoneTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Started252257261
Received at least 1 dose of study drug250257260
Completed220228214
Not completed322947
Withdrew: Adverse event657
Withdrew: Death100
Withdrew: Lost to follow-up5913
Withdrew: Entry criteria not met100
Withdrew: Protocol violation779
Withdrew: Withdrawal by subject6616
Withdrew: Physician decision311
Withdrew: Lack of efficacy311

Outcome measures

PrimaryTime to Discontinuation of Randomized Treatment

Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.

Time frame:
Baseline up to 334 days
Reported as:
Median · days
Time to Discontinuation of Randomized Treatment
daysTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Time to Discontinuation of Randomized TreatmentNA (187 to NA)130 (113 to NA)67 (64 to 77)
Statistical analysis
  • Tadalafil Once a Day vs Sildenafil Citrate On Demand · Regression, Cox · p = <0.001 (P-value: Tadalafil Once a Day versus Sildenafil Citrate On Demand treatment groups. Cox's proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.) · Cox proportional hazard: 0.66 · 97.3% CI 0.51 to 0.85
  • Tadalafil On Demand vs Sildenafil Citrate On Demand · Regression, Cox · p = <0.001 (P-value: Tadalafil On Demand versus Sildenafil Citrate On Demand treatment groups. Cox's proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.) · Cox proportional hazard: 0.49 · 97.3% CI 0.37 to 0.65
  • Tadalafil On Demand vs Tadalafil Once a Day · Regression, Cox · p = 0.033 (P-value: Tadalafil On Demand versus Tadalafil Once a Day treatment groups using Cox's proportional hazards model with factors for randomized treatment group, baseline International Index of Erectile Function-Erectile Function score, and country.) · Cox proportional hazard: 1.32 · 95% CI 1.02 to 1.71
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain

Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 47.92 ± 0.448.60 ± 0.438.86 ± 0.43
Change from Baseline to Week 8 (n=231, 232, 232)8.98 ± 0.459.08 ± 0.459.70 ± 0.44
Change from Baseline to Week 16 (n=167, 146, 101)10.60 ± 0.419.93 ± 0.4210.56 ± 0.45
Change from Baseline to Week 24 (n=141, 116, 81)10.70 ± 0.4310.01 ± 0.4511.05 ± 0.49
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain

Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 41.64 ± 0.161.75 ± 0.161.92 ± 0.16
Change from Baseline to Week 8 (n=231, 232, 232)1.77 ± 0.162.08 ± 0.162.26 ± 0.16
Change from Baseline to Week 16 (n=167, 146, 101)2.37 ± 0.152.25 ± 0.162.66 ± 0.17
Change from Baseline to Week 24 (n=141, 116, 81)2.55 ± 0.152.48 ± 0.162.62 ± 0.18
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain

Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to 4 Weeks0.77 ± 0.100.75 ± 0.100.69 ± 0.10
Change from Baseline to 8 Weeks (n=230, 232, 232)0.96 ± 0.110.90 ± 0.110.87 ± 0.11
Change from Baseline to 16 Weeks (n=167, 146, 101)1.15 ± 0.120.87 ± 0.121.07 ± 0.14
Change from Baseline to 24 Weeks (n=140, 117, 81)1.19 ± 0.120.78 ± 0.131.29 ± 0.14
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)

Participant-assessed diary. Has 5 questions (Question\[Q\]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit\*treatment.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)
percentage of "yes" responsesTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Q1:Change from Baseline to 4 Weeks14.50 (11.82 to 17.18)18.49 (15.83 to 21.14)18.41 (15.77 to 21.05)
Q1:Change from Baseline to 8 Weeks (n=224,231,229)16.62 (14.05 to 19.19)19.88 (17.33 to 22.43)20.41 (17.87 to 22.96)
Q1:Change from Baseline to 16 Weeks (n=166,146,99)18.46 (16.02 to 20.89)19.19 (16.72 to 21.67)20.58 (17.90 to 23.27)
Q1:Change from Baseline to 24 Weeks (n=139,115,81)19.97 (17.78 to 22.15)19.60 (17.33 to 21.86)20.34 (17.94 to 22.74)
Q2:Change from Baseline to 4 Weeks27.48 (23.77 to 31.19)28.56 (24.87 to 32.24)29.64 (25.96 to 33.31)
Q2:Change from Baseline to 8 Weeks (n=224,231,229)31.16 (27.57 to 34.76)31.66 (28.09 to 35.22)34.08 (30.52 to 37.64)
Q2:Change from Baseline to 16 Weeks (n=166,146,99)32.76 (29.38 to 36.14)32.76 (29.33 to 36.20)36.07 (32.38 to 39.76)
Q2:Change from Baseline to 24 Weeks (n=139,115,81)35.83 (32.71 to 38.94)34.70 (31.48 to 37.92)35.93 (32.51 to 39.35)
Q3:Change from Baseline to 4 Weeks41.52 (36.79 to 46.26)41.76 (37.05 to 46.47)44.45 (39.76 to 49.13)
Q3:Change from Baseline to 8 Weeks (n=224,231,229)47.45 (42.65 to 52.26)44.58 (39.80 to 49.35)52.11 (47.36 to 56.86)
Q3:Change from Baseline to 16 Weeks (n=166,146,99)54.26 (49.86 to 58.67)50.62 (46.14 to 55.11)56.96 (52.10 to 61.82)
Q3:Change from Baseline to 24 Weeks (n=139,115,81)56.39 (51.89 to 60.89)53.83 (49.13 to 58.53)56.28 (51.18 to 61.38)
Q4:Change from Baseline to 4 Weeks49.59 (44.22 to 54.97)51.78 (46.44 to 57.12)51.45 (46.13 to 56.76)
Q4:Change from Baseline to 8 Weeks (n=224,231,229)60.86 (55.37 to 66.36)55.59 (50.14 to 61.05)59.28 (53.85 to 64.71)
Q4:Change from Baseline to 16 Weeks (n=166,146,99)66.17 (60.92 to 71.43)63.00 (57.64 to 68.36)66.48 (60.65 to 72.31)
Q4:Change from Baseline to 24 Weeks (n=139,115,81)72.67 (67.46 to 77.89)68.06 (62.58 to 73.54)69.04 (63.06 to 75.02)
Q5:Change from Baseline to 4 Weeks46.12 (40.79 to 51.46)45.71 (40.41 to 51.01)49.63 (44.35 to 54.90)
Q5:Change from Baseline to 8 Weeks (n=224,231,229)53.92 (48.46 to 59.37)50.06 (44.65 to 55.47)55.73 (50.33 to 61.13)
Q5:Change from Baseline to 16 Weeks (n=166,146,99)61.57 (56.26 to 66.88)54.56 (49.16 to 59.96)62.40 (56.55 to 68.25)
Q5:Change from Baseline to 24 Weeks (n=139,115,81)65.45 (60.29 to 70.60)62.17 (56.78 to 67.57)66.57 (60.72 to 72.42)
SecondaryGlobal Assessment Questions (GAQ)

The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?

Time frame:
24 weeks
Reported as:
Number · participants
Global Assessment Questions (GAQ)
participantsTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Q1:Treatment improved erections? Yes218219203
Q1:Treatment improved erections? No202334
Q1: Treatment improved erections? No Response141524
Q2:Treatment improved ability to engage? Yes209214204
Q2:Treatment improved ability to engage? No1478
Q2: Treatment improved ability to engage? No Respo293649
SecondaryNumber of Treatment Switches

The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).

Time frame:
Baseline through 24 weeks
Reported as:
Mean · number of treatment switches
Number of Treatment Switches
number of treatment switchesTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Number of Treatment Switches1.2 ± 0.41.2 ± 0.51.3 ± 0.5
SecondaryPatterns of Erectile Dysfunction Treatment Change

Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.

Time frame:
Baseline through 24 weeks
Reported as:
Number · participants
Patterns of Erectile Dysfunction Treatment Change
participantsEntire Study Population
No Treatment Intake3
No Switch409
From Once a Day to Any On Demand95
From Any On Demand to Once a Day84
From Any On Demand to Any On Demand97
Returning Back to Randomized Treatment35
Other Treatment Sequence47
SecondaryReasons for Discontinuation of Randomized Erectile Dysfunction Treatment

The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.

Time frame:
Baseline through 24 weeks
Reported as:
Number · participants
Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment
participantsTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Slow onset of action5910
Completed treatment111
Lack of efficacy (hardness of erection)465555
Lack of efficacy (duration of erection)71124
Lack of confidence in medication working each time352
Adverse event71016
Feel medication controls my sexual life107
Non-desired spontaneous erections240
Time constraints due to short drug action window1011
Partner's request023
Don't want to take a pill every day0270
Prefer a pill every day, not on demand20028
Participant discontinuation from the trial111114
Participant did not take any study drug201
Participants without discontinuation event14612289
SecondaryNumber of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments

The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.

Time frame:
8 weeks up to 334 days
Reported as:
Median · days
Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments
daysTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor TreatmentsNA (NA to NA)NA (200 to NA)187 (165 to NA)
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain

Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 43.21 ± 0.203.22 ± 0.203.53 ± 0.20
Change from Baseline to Week 8 (n=231, 232, 232)3.69 ± 0.203.15 ± 0.203.95 ± 0.20
Change from Baseline to Week 16 (n=167, 146, 101)4.38 ± 0.203.60 ± 0.214.41 ± 0.23
Change from Baseline to Week 24 (n=141, 116, 81)4.48 ± 0.213.71 ± 0.224.70 ± 0.24
SecondaryChange From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain

Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 42.46 ± 0.162.58 ± 0.152.72 ± 0.15
Change from Baseline to Week 8 (n=230, 231, 233)2.80 ± 0.162.85 ± 0.162.98 ± 0.16
Change from Baseline to Week 16 (n=167, 145, 101)3.34 ± 0.153.09 ± 0.153.48 ± 0.17
Change from Baseline to Week 24 (n=141, 116, 81)3.50 ± 0.153.24 ± 0.163.41 ± 0.17
SecondaryErectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks

The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit\*treatment.

Time frame:
4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
EDITS at Week 472.36 (69.64 to 75.08)75.20 (72.51 to 77.90)71.98 (69.28 to 74.67)
EDITS at Week 8 (n=231, 235, 231)75.28 (72.51 to 78.05)76.64 (73.88 to 79.39)72.74 (69.99 to 75.49)
EDITS at Week 16 (n=168, 147, 100)79.64 (77.00 to 82.29)77.66 (74.97 to 80.35)76.64 (73.71 to 79.56)
EDITS at Week 24 (n=141, 118, 80)81.01 (78.44 to 83.58)78.75 (76.10 to 81.41)77.98 (75.09 to 80.87)
SecondaryChange From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)

The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score\*treatment (if p\<0.10).

Time frame:
Baseline, 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Sexual Self-Confidence Domain (n=196, 203, 185)0.93 (0.83 to 1.03)0.90 (0.81 to 1.00)0.73 (0.64 to 0.83)
Spontaneity Domain (n=197, 202, 186)0.13 (0.07 to 0.20)0.11 (0.04 to 0.18)0.02 (-0.05 to 0.09)
Time Concerns Domain (n=196, 200, 184)-0.08 (-0.16 to -0.01)-0.20 (-0.27 to -0.12)0.04 (-0.03 to 0.12)
SecondaryChange From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 427.65 (24.65 to 30.65)29.26 (26.29 to 32.23)29.50 (26.53 to 32.48)
Change from Baseline to Week 8 (n=230, 232, 231)31.42 (28.23 to 34.61)31.07 (27.90 to 34.24)31.15 (27.99 to 34.31)
Change from Baseline to Week 16 (n=167, 146, 101)37.59 (34.58 to 40.61)32.90 (29.84 to 35.96)37.32 (34.03 to 40.60)
Change from Baseline to Week 24 (n=140, 117, 81)39.37 (36.31 to 42.43)34.96 (31.79 to 38.13)37.46 (34.05 to 40.87)
SecondaryChange From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem \[items 9-12\]; Overall Relationship \[items 13-14\]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x\[(actual raw score-lowest possible raw score)/possible raw score range\]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 423.43 (20.32 to 26.54)23.04 (19.96 to 26.13)25.03 (21.94 to 28.12)
Change from Baseline to Week 8 (n=230, 233, 232)26.97 (23.83 to 30.11)26.10 (22.97 to 29.22)27.14 (24.03 to 30.25)
Change from Baseline to Week 16 (n=167, 147, 100)33.15 (30.28 to 36.02)28.33 (25.41 to 31.25)31.86 (28.71 to 35.00)
Change from Baseline to Week 24 (n=140, 116, 81)33.74 (30.64 to 36.84)30.42 (27.21 to 33.63)31.66 (28.21 to 35.12)
SecondaryChange From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to 4 Weeks25.18 (21.95 to 28.41)24.10 (20.90 to 27.30)26.59 (23.39 to 29.79)
Change from Baseline to 8 Weeks (n=230, 233, 233)29.14 (25.93 to 32.35)27.80 (24.60 to 30.99)28.92 (25.75 to 32.10)
Change from Baseline to 16 Weeks (n=167, 147, 100)35.23 (32.20 to 38.26)29.46 (26.37 to 32.55)33.85 (30.50 to 37.20)
Change from Baseline to 24 Weeks (n=140, 116, 81)35.86 (32.59 to 39.12)31.14 (27.75 to 34.52)33.52 (29.88 to 37.16)
SecondaryChange From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire

SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.

Time frame:
Baseline, 4, 8, 16, and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
units on a scaleTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Change from Baseline to Week 419.92 (16.41 to 23.44)21.10 (17.63 to 24.57)22.00 (18.52 to 25.48)
Change from Baseline to Week 8 (n=229, 232, 232)22.75 (19.19 to 26.31)22.96 (19.43 to 26.50)23.74 (20.22 to 27.27)
Change from Baseline to Week 16 (n=166, 147, 100)29.63 (26.46 to 32.79)26.96 (23.74 to 30.17)28.57 (25.07 to 32.08)
Change from Baseline to Week 24 (n=139, 116, 81)30.28 (26.93 to 33.62)29.93 (26.43 to 33.43)28.74 (24.93 to 32.56)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil On Demand—8/250 (3.2%)106/250 (42.4%)
Tadalafil Once a Day—4/257 (1.6%)80/257 (31.1%)
Sildenafil Citrate On Demand—2/260 (0.8%)103/260 (39.6%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Infections and infestationsInfections and infestations2/2500/2570/260
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)2/2501/2571/260
Congenital, familial and genetic disordersCongenital, familial and genetic disorders1/2500/2570/260
Pulmonary sequestrationCongenital, familial and genetic disorders1/2500/2570/260
DiverticulitisInfections and infestations1/2500/2570/260
ParotitisInfections and infestations1/2500/2570/260
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/2500/2570/260
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders1/2500/2570/260
Oesophageal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2500/2570/260
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2500/2570/260
Most frequent other events
Most frequent other events
EventTadalafil On DemandTadalafil Once a DaySildenafil Citrate On Demand
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications44/25019/25740/260
Gastrointestinal disordersGastrointestinal disorders21/25030/25710/260
Nervous system disordersNervous system disorders14/25019/25727/260
OverdoseInjury, poisoning and procedural complications21/2508/25723/260
HeadacheNervous system disorders10/25014/25723/260
Infections and infestationsInfections and infestations17/25010/25710/260
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders16/25017/2579/260
Vascular disordersVascular disorders11/2503/25717/260
Intentional overdoseInjury, poisoning and procedural complications16/2505/2578/260

Baseline characteristics

Age Continuous
Age Continuous(years)Tadalafil On DemandTadalafil Once a DaySildenafil Citrate On DemandTotal
Mean53.2 ± 11.5752.9 ± 11.6953.0 ± 11.7653.0 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil On DemandTadalafil Once a DaySildenafil Citrate On DemandTotal
Female0000
Male252257261770
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tadalafil On DemandTadalafil Once a DaySildenafil Citrate On DemandTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American24410
White248251254753
More than one race0011
Unknown or Not Reported2226
Region of Enrollment
Region of Enrollment(participants)Tadalafil On DemandTadalafil Once a DaySildenafil Citrate On DemandTotal
Portugal65718
France99102100301
Greece98926
Poland15161647
Spain484952149
Romania20222163
Germany454547137
United Kingdom1010929
08

Study locations

45 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carpentras, 84200, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chambery, 73000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Bouexiere, 35340, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69437, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13009, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34090, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Murs-Erigne, 49610, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44300, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35 700, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse, 31000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Giengen, 89537, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grevenbroich, 41515, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Holzminden, D-37603, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koblenz, 56068, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leverkusen, 51375, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Luebeck, 23552, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marburg, 35039, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muehlacker, D-75417, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warburg, 34414, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Larissa, 41221, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 56429, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kutno, 99-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Legionowo, 05-120, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-008, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 00-909, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 53-532, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto, 4202-451, Portugal
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucharest, 050653, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 400046, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alcorcon, 28922, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aravaca, 28023, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coslada, 28820, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gijon, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28040, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Málaga, 29007, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Sebastian De Los Reyes, 28702, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vigo, 36211, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fowey, Cornwall PL23 1DT, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, County Durham DH1 2QW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plymouth, Devon PL6 7TH, United Kingdom
09

References and documents

Publications

  • Buvat J, Buttner H, Hatzimouratidis K, Vendeira PA, Moncada I, Boehmer M, Henneges C, Boess FG. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med. 2013 Jun;10(6):1592-602. doi: 10.1111/jsm.12130. Epub 2013 Apr 2. PubMed 23551622 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 13, 2010
Start
May 2010
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Oct 19, 2012
Last update
Oct 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01122264
Responsible party
Sponsor
First posted
May 13, 2010
Start date
May 2010
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Oct 19, 2012
Last update
Oct 19, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion